Some commentary from Macquarie emailed yesterday, this looks to...

  1. 8 Posts.

    Some commentary from Macquarie emailed yesterday, this looks to be a major issue ATM and keeping the share price well below the 4.77 high.

    Emerging Leaders
    Acrux ACR Underperform
    Rebates remain stubbornly high

    * Eli Lilly reported Axiron 4Q net sales at US$23.9m (vs. Macq at US$22.6m).
    * Solid net sales number due to lower than expected rebate; however, it appears that the rebate has increased on a seasonally adjusted basis.
    * Underperform. Positive that Q4 rebates were lower than Q3, but still increased on a seasonally adjusted basis and concern about slowing market growth.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
1.7¢
Change
0.001(6.25%)
Mkt cap ! $6.931M
Open High Low Value Volume
1.6¢ 1.7¢ 1.6¢ $6.279K 376.7K

Buyers (Bids)

No. Vol. Price($)
3 741559 1.6¢
 

Sellers (Offers)

Price($) Vol. No.
1.7¢ 193057 2
View Market Depth
Last trade - 16.10pm 27/06/2025 (20 minute delay) ?
ACR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.